BrainsWay Ltd. (NASDAQ:BWAY) Sees Significant Increase in Short Interest

BrainsWay Ltd. (NASDAQ:BWAY) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 125,100 shares, an increase of 126.2% from the February 28th total of 55,300 shares. Based on an average trading volume of 65,800 shares, the short-interest ratio is currently 1.9 days. Approximately 0.8% of the company’s stock are sold short.

BrainsWay Stock Performance

NASDAQ:BWAY opened at $9.30 on Friday. The company has a market capitalization of $175.09 million, a P/E ratio of 93.01 and a beta of 1.29. The stock’s 50 day moving average price is $10.27 and its 200 day moving average price is $9.77. BrainsWay has a 52 week low of $4.61 and a 52 week high of $11.79.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of BrainsWay in a research note on Wednesday, March 12th.

Institutional Trading of BrainsWay

Several large investors have recently added to or reduced their stakes in BWAY. Valor Management LLC acquired a new stake in shares of BrainsWay in the 4th quarter valued at $19,838,000. Two Sigma Advisers LP raised its holdings in BrainsWay by 32.6% during the fourth quarter. Two Sigma Advisers LP now owns 60,600 shares of the company’s stock valued at $571,000 after buying an additional 14,900 shares in the last quarter. Two Sigma Investments LP raised its holdings in BrainsWay by 2.0% during the fourth quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock valued at $875,000 after buying an additional 1,786 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in shares of BrainsWay in the fourth quarter worth about $44,000. Finally, Cubist Systematic Strategies LLC boosted its stake in shares of BrainsWay by 14.6% during the 4th quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock worth $181,000 after acquiring an additional 2,446 shares in the last quarter. 30.11% of the stock is owned by institutional investors.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.